Table 2.
Interaction between hyperandrogenemia and hypothalamic–pituitary–gonadal axis activation in primary severe insulin resistance
| Syndrome | n | Age, years | Total testosterone, ng/dL |
|---|---|---|---|
| Prepuberty | 13 | 7 (7-10) | 10.0 (10.0-20.0) |
| Generalized lipodystrophy | 10 | 7 (7) | 10.0 (5.3-15.2) |
| Partial lipodystrophy | 2 | 10 (9.5-10.5) | 20.0 (20.0-20.0) |
| Insulin signaling disorder | 1 | 13 | 20.0 |
| Midpuberty | 37 | 13 (11-15) | 25.4 (20.0-41.0) |
| Generalized lipodystrophy | 14 | 13 (11-14) | 20.2 (10.0-29.8) |
| Partial lipodystrophy | 14 | 14 (12-15) | 20.0 (12.5-37.8) |
| Insulin signaling disorder | 9 | 12 (10-15) | 49.7 (30.0-83.0) |
| Postpuberty | 112 | 27 (18-39) | 24.2 (20.0-57.3) |
| Generalized lipodystrophy | 39 | 20 (16-23) | 23.0 (10.0-44.1) |
| Partial lipodystrophy | 52 | 35 (27-43) | 20.0 (20.0-42.3) |
| Insulin signaling disorder | 21 | 25 (18-39) | 52.3 (41.0-239) |
| Postmenopause | 32 | 53 (49-58) | 20.0 (20.0-44.7) |
| Generalized lipodystrophy | 2 | 45 (38-52) | 15.0 (12.5-17.5) |
| Partial lipodystrophy | 19 | 53 (47-57) | 20.0 (20.0-35.0) |
| Insulin signaling disorder | 11 | 52 (51-57) | 29.3 (20.0-100) |
| Total | 194 | 27 (42-15) | 20.8 (49.7-18.3) |
Median (interquartile range) values presented. Summary data for HPG status are presented in bold font.